Evaluation of the SARS-CoV-2-IgG response in outpatients by five commercial immunoassays
Abstract: Commercially available immunoassays have been developed for sensitive and specific detection of antibodies against SARS-CoV-2. While high sensitivity has been reported in hospitalized COVID-19 patients, little is known about the performance of the assays in ambulatory patients. Therefore, we evaluated the SARS-CoV-2-IgG response in 51 SASR-CoV-2-PCR-confirmed outpatients with five commercial immunoassays. The sensitivity in serum samples, collected at a median of 24 days after onset of symptoms, detected by the Anti-SARS-CoV-2-ELISA IgG (Euroimmun), EDI(TM) Novel Coronavirus COVID-19 IgG ELISA (Epitope Diagnostics), Liaison® SARS-CoV-2 S1/S2 IgG (Diasorin), SARS-CoV-2 IgG on the Architect(TM) i2000 (Abbott), and Elecsys® Anti-SARS-CoV-2 (IgM/IgA/IgG) on the cobas(TM) e801 (Roche) was 84.3%, 78.4%, 74.5%, 86.3%, and 88.2%, respectively. The sensitivity in serum samples, collected >20 days after onset of symptoms, varied between 75.0% and 90.0%, and in samples, collected at least 28...
- Standort
-
Deutsche Nationalbibliothek Frankfurt am Main
- Umfang
-
Online-Ressource
- Sprache
-
Englisch
- Erschienen in
-
Evaluation of the SARS-CoV-2-IgG response in outpatients by five commercial immunoassays ; volume:8 ; day:16 ; month:09 ; year:2020
GMS infectious diseases ; 8 (16.09.2020)
- Klassifikation
-
Medizin, Gesundheit
- Urheber
-
Wellinghausen, Nele
Voss, Meike
Ivanova, Ralitsa
Deininger, Susanne
- DOI
-
10.3205/id000066
- URN
-
urn:nbn:de:0183-id0000666
- Rechteinformation
-
Open Access; Open Access; Open Access; Der Zugriff auf das Objekt ist unbeschränkt möglich.
- Letzte Aktualisierung
-
14.08.2025, 10:48 MESZ
Datenpartner
Dieses Objekt wird bereitgestellt von:
Deutsche Nationalbibliothek. Bei Fragen zum Objekt wenden Sie sich bitte an den Datenpartner.
Deutsche Nationalbibliothek. Bei Fragen zum Objekt wenden Sie sich bitte an den Datenpartner.
Beteiligte
- Wellinghausen, Nele
- Voss, Meike
- Ivanova, Ralitsa
- Deininger, Susanne
Ähnliche Objekte (12)
Development and multicenter performance evaluation of fully automated SARS-CoV-2 IgM and IgG immunoassays
Diagnostic performance of commercial IgM and IgG enzyme-linked immunoassays (ELISAs) for diagnosis of Zika virus infection
Commercial immunoassays in biomarkers studies: researchers beware! 1)
Immunoassays
Assessment of immune response to SARS-CoV-2 with fully automated MAGLUMI 2019-nCoV IgG and IgM chemiluminescence immunoassays
Pooled analysis of laboratory-based SARS-CoV-2 antigen immunoassays
Evaluation of four commercial, fully automated SARS-CoV-2 antibody tests suggests a revision of the Siemens SARS-CoV-2 IgG assay
Diagnostic performance between in-house and commercial SARS-CoV-2 serological immunoassays including binding-specific antibody and surrogate virus neutralization test (sVNT)
The prevalence of vascular complications in SARS-CoV-2 infected outpatients
Development of rapid automated chemiluminescence microarray immunoassays for SARS-CoV-2 serological assessments
Rheumatoid factor and falsely elevated results in commercial immunoassays: data from an early arthritis cohort
Clinical performance of different SARS‐CoV‐2 IgG antibody tests
Development and multicenter performance evaluation of fully automated SARS-CoV-2 IgM and IgG immunoassays
Diagnostic performance of commercial IgM and IgG enzyme-linked immunoassays (ELISAs) for diagnosis of Zika virus infection
Commercial immunoassays in biomarkers studies: researchers beware! 1)
Immunoassays
Assessment of immune response to SARS-CoV-2 with fully automated MAGLUMI 2019-nCoV IgG and IgM chemiluminescence immunoassays
Pooled analysis of laboratory-based SARS-CoV-2 antigen immunoassays
Evaluation of four commercial, fully automated SARS-CoV-2 antibody tests suggests a revision of the Siemens SARS-CoV-2 IgG assay
Diagnostic performance between in-house and commercial SARS-CoV-2 serological immunoassays including binding-specific antibody and surrogate virus neutralization test (sVNT)
The prevalence of vascular complications in SARS-CoV-2 infected outpatients
Development of rapid automated chemiluminescence microarray immunoassays for SARS-CoV-2 serological assessments
Rheumatoid factor and falsely elevated results in commercial immunoassays: data from an early arthritis cohort
Clinical performance of different SARS‐CoV‐2 IgG antibody tests
Development and multicenter performance evaluation of fully automated SARS-CoV-2 IgM and IgG immunoassays
Diagnostic performance of commercial IgM and IgG enzyme-linked immunoassays (ELISAs) for diagnosis of Zika virus infection
Commercial immunoassays in biomarkers studies: researchers beware! 1)
Immunoassays
Assessment of immune response to SARS-CoV-2 with fully automated MAGLUMI 2019-nCoV IgG and IgM chemiluminescence immunoassays
Pooled analysis of laboratory-based SARS-CoV-2 antigen immunoassays
Evaluation of four commercial, fully automated SARS-CoV-2 antibody tests suggests a revision of the Siemens SARS-CoV-2 IgG assay
Diagnostic performance between in-house and commercial SARS-CoV-2 serological immunoassays including binding-specific antibody and surrogate virus neutralization test (sVNT)
The prevalence of vascular complications in SARS-CoV-2 infected outpatients
Development of rapid automated chemiluminescence microarray immunoassays for SARS-CoV-2 serological assessments
Rheumatoid factor and falsely elevated results in commercial immunoassays: data from an early arthritis cohort